A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC) Clinical Trial

Official title:
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma

Status Completed

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)

Clinical Trial Details

NCT number	NCT03430843
Study type	Interventional
Source	BeiGene
Contact
Status	Completed
Phase	Phase 3
Start date	January 26, 2018
Completion date	December 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06078657` - IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)	Phase 2
Active, not recruiting	`NCT03708328` - A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT03957590` - Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC	Phase 3
Active, not recruiting	`NCT05342636` - A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)	Phase 1/Phase 2
Active, not recruiting	`NCT04210115` - Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)	Phase 3
Not yet recruiting	`NCT05473156` - A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT03783442` - A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma	Phase 3
Enrolling by invitation	`NCT04839471` - BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)	Phase 2